Advertisement

Search Results

Advertisement



Your search for Allen S. Lichter, MD, FASCO, and Mark J. Ratain, MD,Allen S. Lichter, MD, FASCO, and Mark J. Ratain, MD matches 3 pages

Showing 1 - 3


issues in oncology

Empowering the FDA to Require Dose Optimization of All New Oncology Drugs

The vast majority of drugs used outside of oncology are evaluated in randomized dose-ranging trials to optimize the therapeutic index prior to the pivotal phase III trial. No one would think of dosing a statin or an antibiotic at the highest dose patients could tolerate, especially if that dose...

cost of care

How the First International Summit on Interventional Pharmacoeconomics Is Sparking Discussion on Reducing Cancer Costs

Three years ago, former Chief Executive Officer of ASCO, Allen S. Lichter, MD, Laurence H. Baker, DO, Professor in the Departments of Internal Medicine and Pharmacology at the University of Michigan Medical School in Ann Arbor; Leonard Saltz, MD, a gastrointestinal oncologist at Memorial Sloan...

issues in oncology
cost of care

How to Save Billions on Cancer Care Costs: The Potential of Value-Based Prescribing in Oncology

IT IS TIME for value-based prescribing—the reduction of prescribing costs using basic pharmacologic principles—to be tested and deployed in oncology. The savings are real and there for the taking. If you are concerned about the high costs in cancer care, here is a chance to get maximum value for...

Advertisement

Advertisement



Advertisement